Speaker: Thomas Schirrmann received his PhD in immunology for his work in adoptive cellular immune therapy with chimeric antigen receptor (CAR) Natural Killer (NK) cellsfrom the Humboldt University and worked as scientist and research group leader in research institutions such as Max-Delbrueck-Center of Molecular Medicine (MDC), Charité Hospital in Berlin and University of Braunschweig. In over 20 years of his research he gained a broad interdisciplinary expertise in recombinant antibody technologies, protein engineering and expression, bi-and multi-specific antibodies, fusion proteins, gene-modified immune cells and immunotherapies. Thomas is author of more than 70 research articles and inventor of several patents. He is co-founder and CEO of YUMAB a fast-growing biotech company. Thomas received prizes for his outstanding work in translating science into commercialization. Currently, Thomas also acts as CEO of two YUMAB spin-offs, YUMAB, Inc. (USA; founded 2017) and CORAT Therapeutics GmbH (Germany; founded 2020).
Reference:
Bertoglio et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. bioRxiv preprint doi: https://doi.org/10.1101/2020.06.05.135921 (version posted June 5, 2020).
Speaker: Dr. Janice Reichert is an internationally-recognized expert in the development of antibody therapeutics. She is Executive Director of The Antibody Society, a non-profit association representing individuals and organizations that engage in antibody research or development. Dr. Reichert is also Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development, and Founder and Managing Director of Reichert Biotechnology Consulting LLC, a pharmaceutical business intelligence research firm. Dr. Reichert writes frequently on development trends for antibody therapeutics, including the annual ‘Antibodies to watch’ articles published in mAbs, and she has presented her research results as an invited speaker at conferences held worldwide.
References:
Kaplon et al. Antibodies to Watch in 2020. mAbs 2020.
Coronavirus in the Crosshairs
